Vestmark Advisory Solutions’s Recursion Pharmaceuticals RXRX Stock Holding History

Vestmark Advisory Solutions’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Buy	726,986 +122,230	+20%	+$472K	0.02%	582
2025 Q4	$2.47M	Sell	604,756 -16,303	-3%	-$80.7K	0.03%	514
2025 Q3	$3.03M	Sell	621,059 -718,080	-54%	-$3.77M	0.06%	331
2025 Q2	$6.78M	Buy	1,339,139 +632,900	+90%	+$3.11M	0.1%	154
2025 Q1	$3.74M	Sell	706,239 -138,915	-16%	-$1.01M	0.1%	244
2024 Q4	$6.36M	Buy	845,154 +112,221	+15%	+$754K	0.22%	92
2024 Q3	$4.83M	Sell	732,933 -51,964	-7%	-$373K	0.18%	115
2024 Q2	$5.89M	Sell	784,897 -115,122	-13%	-$1M	0.25%	86
2024 Q1	$8.97M	Buy	900,019 +427,763	+91%	+$4.76M	0.39%	55
2023 Q4	$4.66M	Buy	+472,256	New	+$3.37M	0.24%	102

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vestmark Advisory Solutions's RXRX Position: Q1 2026 in Review

Vestmark Advisory Solutions increased its Recursion Pharmaceuticals (RXRX) stake by 20% in Q1 2026, buying an estimated $472K and bringing the position to 726,986 shares worth $2.23M. The position accounts for 0.02% of the portfolio, ranked #582.

Vestmark Advisory Solutions first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $8.97M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Vestmark Advisory Solutions held 726,986 shares of Recursion Pharmaceuticals worth $2.23M as of Q1 2026.
Vestmark Advisory Solutions bought 122,230 Recursion Pharmaceuticals shares in Q1 2026, an estimated $472K.
Recursion Pharmaceuticals made up 0.02% of Vestmark Advisory Solutions's portfolio in Q1 2026, its #582 holding.
Vestmark Advisory Solutions first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Vestmark Advisory Solutions's Recursion Pharmaceuticals position peaked at $8.97M in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.